X4 Pharmaceuticals
XFOR
62 hedge funds and large institutions have $108M invested in X4 Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 17 closing their positions.
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
3% more funds holding
Funds holding: 60 → 62 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.86% less ownership
Funds ownership: 3.09% → 2.23% (-0.86%)
22% less capital invested
Capital invested by funds: $139M → $108M (-$30.9M)
56% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$12.1M |
| 2 |
Millennium Management
New York
|
+$3.24M |
| 3 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$2.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.35M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$874K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.94M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.62M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$2.04M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.91M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$937K |
XFOR Hedge Fund Activity: Q2 2021 in Review
62 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2021, worth a combined $108M — down 22% from $139M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new XFOR positions and 17 closed out — a net gain of 2 holders — while 8 added to existing stakes and 18 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $12.1M. The largest seller was BlackRock, cutting an estimated $6.94M.
- 62 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2021, up from 60 in Q1 2021.
- Funds reported $108M of X4 Pharmaceuticals stock for Q2 2021, down 22% quarter-over-quarter.
- 19 funds opened new X4 Pharmaceuticals positions in Q2 2021 and 17 closed out, a net change of +2 holders.
- The largest X4 Pharmaceuticals buyer in Q2 2021 was AIGH Capital Management, an estimated $12.1M added.
- The largest X4 Pharmaceuticals seller in Q2 2021 was BlackRock, an estimated $6.94M sold.
Based on aggregated 13F filings for Q2 2021.